V
Vincent J. Picozzi
Researcher at Virginia Mason Medical Center
Publications - 119
Citations - 5982
Vincent J. Picozzi is an academic researcher from Virginia Mason Medical Center. The author has contributed to research in topics: Pancreatic cancer & Cancer. The author has an hindex of 34, co-authored 106 publications receiving 5254 citations. Previous affiliations of Vincent J. Picozzi include Stanford University.
Papers
More filters
Journal ArticleDOI
Reduction by Granulocyte Colony-Stimulating Factor of Fever and Neutropenia Induced by Chemotherapy in Patients with Small-Cell Lung Cancer
Jeffrey Crawford,Howard Ozer,Ronald G. Stoller,David H. Johnson,Gary H. Lyman,Imad A. Tabbara,Mark G. Kris,John Grous,Vincent J. Picozzi,Gregory Rausch,Roy E. Smith,William J. Gradishar,Anne M. Yahanda,Martha Vincent,Morgan Stewart,John A. Glaspy +15 more
TL;DR: A randomized clinical trial to test the hypothesis that recombinant methionyl granulocyte colony-stimulating factor (G-CSF) can reduce chemotherapy-related neutropenia in patients with cancer and the clinical implications.
Journal ArticleDOI
Safety and Survival With GVAX Pancreas Prime and Listeria Monocytogenes–Expressing Mesothelin (CRS-207) Boost Vaccines for Metastatic Pancreatic Cancer
Dung T. Le,Andrea Wang-Gillam,Vincent J. Picozzi,Tim F. Greten,Todd S. Crocenzi,Gregory M. Springett,Michael A. Morse,Herbert J. Zeh,Deirdre Jill Cohen,Robert L. Fine,Beth Onners,Jennifer N. Uram,Daniel A. Laheru,Eric R. Lutz,Sara Solt,Aimee Murphy,Justin Skoble,Ed Lemmens,John Grous,Thomas W. Dubensky,Dirk G. Brockstedt,Elizabeth M. Jaffee +21 more
TL;DR: Heterologous prime/boost vaccination with Cy/GVAX and CRS-207 extended survival for patients with pancreatic cancer, with minimal toxicity.
Journal ArticleDOI
Interferon-based adjuvant chemoradiation therapy after pancreaticoduodenectomy for pancreatic adenocarcinoma
TL;DR: Overall survival may be improved for patients with adenocarcinoma in the pancreatic head using an adjuvant interferon-based chemoradiation protocol, and actuarial 2-year and 5-year overall survival rates suggest a potential for improved long-term survival.
Journal ArticleDOI
Combined modality treatment of resectable and borderline resectable pancreas cancer: expert consensus statement.
Ross A. Abrams,Andrew M. Lowy,Eileen M. O'Reilly,Robert A. Wolff,Vincent J. Picozzi,Peter W.T. Pisters +5 more
TL;DR: This poster presents a poster presented at the 2016 American Academy of Gastrointestinal Oncology Congress, entitled “Towards a Surgeons’ View of Pancreaticobiliary Cancer: Pathophysiology and Tumor Discovery,” which addressed the role of inflammation in the development of pancreas-based cancer.
Journal ArticleDOI
Reduction by Granulocyte Colony-Stimulating Factor of Fever and Neutropenia Induced by Chemotherapy in Patients with Small-Cell Lung Cancer
Jeffrey Crawford,Howard Ozer,Ronald G. Stoller,David H. Johnson,Gary H. Lyman,Imad A. Tabbara,Mark G. Kris,John Grous,Vincent J. Picozzi,Gregory Rausch,Roy E. Smith,William J. Gradishar,Anne M. Yahanda,Martha Vincent,Morgan Stewart,John A. Glaspy +15 more
TL;DR: The use of G-CSF as an adjunct to chemotherapy in patients with small-cell cancer of the lung was well tolerated and led to reductions in the incidence of fever with neutropenia and culture-confirmed infections, and in the total number of days of treatment with intravenous antibiotics and days of hospitalization.